Company profile PSTX
There is not enough data for Poseida Therapeutics - biopharmaceutical company to provide analysis
There is not enough data for Poseida Therapeutics - biopharmaceutical company to provide correlation calculation
There is not enough data for Poseida Therapeutics - biopharmaceutical company to provide analysis
There is not enough data for Poseida Therapeutics careers to provide analysis
There is not enough data for Poseida Therapeutics careers to provide correlation calculation
There is not enough data for Poseida Therapeutics careers to provide analysis
After 39 days of this quarter the interest is at 51.0. Based on that we can calculate that during remaining 52 days it will total up to 119.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 35 | 217 520.0% QoQ | 34 -84.3% QoQ | 94 176.5% QoQ |
| 2020 | 120 242.9% YoY 27.7% QoQ | 165 -24.0% YoY 37.5% QoQ | 154 352.9% YoY -6.7% QoQ | 215 128.7% YoY 39.6% QoQ |
| 2021 | 159 32.5% YoY -26.0% QoQ | 65 -60.6% YoY -59.1% QoQ | 51 -66.9% YoY -21.5% QoQ | 358 66.5% YoY 602.0% QoQ |
| 2022 | 119 -25.2% YoY -66.8% QoQ | 17 -73.8% YoY -85.7% QoQ | 133 160.8% YoY 682.4% QoQ | 240 -33.0% YoY 80.5% QoQ |
| 2023 | 98 -17.6% YoY -59.2% QoQ | 171 905.9% YoY 74.5% QoQ | 109 -18.0% YoY -36.3% QoQ | 107 -55.4% YoY -1.8% QoQ |
| 2024 | 51 -48.0% YoY -52.3% QoQ | - | - | - |
The average 5 years interest of Poseida Therapeutics stock was 10.39 per week. The last year interest of Poseida Therapeutics stock compared to the last 5 years has changed by -13.38%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 0.45%.
There is not enough data for Poseida Therapeutics news to provide analysis
There is not enough data for Poseida Therapeutics news to provide correlation calculation
There is not enough data for Poseida Therapeutics news to provide analysis
There is not enough data for autologous chimeric antigen receptor T cell (CAR-T) to provide analysis
There is not enough data for autologous chimeric antigen receptor T cell (CAR-T) to provide correlation calculation
There is not enough data for autologous chimeric antigen receptor T cell (CAR-T) to provide analysis
There is not enough data for metastatic castrate resistant prostate cancer (mCRPC) to provide analysis
There is not enough data for metastatic castrate resistant prostate cancer (mCRPC) to provide correlation calculation
There is not enough data for metastatic castrate resistant prostate cancer (mCRPC) to provide analysis
There is not enough data for relapsed/refractory multiple myeloma to provide analysis
There is not enough data for relapsed/refractory multiple myeloma to provide correlation calculation
There is not enough data for relapsed/refractory multiple myeloma to provide analysis
After 39 days of this quarter the interest is at 267.0. Based on that we can calculate that during remaining 52 days it will total up to 623.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 306 | 412 34.6% QoQ | 434 5.3% QoQ | 380 -12.4% QoQ |
| 2020 | 401 31.0% YoY 5.5% QoQ | 417 1.2% YoY 4.0% QoQ | 435 0.2% YoY 4.3% QoQ | 471 23.9% YoY 8.3% QoQ |
| 2021 | 435 8.5% YoY -7.6% QoQ | 384 -7.9% YoY -11.7% QoQ | 402 -7.6% YoY 4.7% QoQ | 440 -6.6% YoY 9.5% QoQ |
| 2022 | 643 47.8% YoY 46.1% QoQ | 619 61.2% YoY -3.7% QoQ | 517 28.6% YoY -16.5% QoQ | 494 12.3% YoY -4.4% QoQ |
| 2023 | 724 12.6% YoY 46.6% QoQ | 643 3.9% YoY -11.2% QoQ | 597 15.5% YoY -7.2% QoQ | 585 18.4% YoY -2.0% QoQ |
| 2024 | 267 -63.1% YoY -54.4% QoQ | - | - | - |
The average 5 years interest of solid tumors was 38.34 per week. The last year interest of solid tumors compared to the last 5 years has changed by 25.04%. The interest for solid tumors is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 46.02%.
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. B cell malignancies expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 79 | 34 -57.0% QoQ | 210 517.6% QoQ | 196 -6.7% QoQ |
| 2020 | 49 -38.0% YoY -75.0% QoQ | 134 294.1% YoY 173.5% QoQ | 219 4.3% YoY 63.4% QoQ | 155 -20.9% YoY -29.2% QoQ |
| 2021 | 103 110.2% YoY -33.5% QoQ | 117 -12.7% YoY 13.6% QoQ | 146 -33.3% YoY 24.8% QoQ | 138 -11.0% YoY -5.5% QoQ |
| 2022 | 132 28.2% YoY -4.3% QoQ | 77 -34.2% YoY -41.7% QoQ | 118 -19.2% YoY 53.2% QoQ | 128 -7.2% YoY 8.5% QoQ |
| 2023 | 164 24.2% YoY 28.1% QoQ | 85 10.4% YoY -48.2% QoQ | 87 -26.3% YoY 2.4% QoQ | 132 3.1% YoY 51.7% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of B cell malignancies was 9.63 per week. The last year interest of B cell malignancies compared to the last 5 years has changed by -16.72%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -19.64%.
After 39 days of this quarter the interest is at 172.0. Based on that we can calculate that during remaining 52 days it will total up to 401.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 438 | 554 26.5% QoQ | 616 11.2% QoQ | 620 0.6% QoQ |
| 2020 | 817 86.5% YoY 31.8% QoQ | 599 8.1% YoY -26.7% QoQ | 561 -8.9% YoY -6.3% QoQ | 503 -18.9% YoY -10.3% QoQ |
| 2021 | 442 -45.9% YoY -12.1% QoQ | 382 -36.2% YoY -13.6% QoQ | 385 -31.4% YoY 0.8% QoQ | 333 -33.8% YoY -13.5% QoQ |
| 2022 | 406 -8.1% YoY 21.9% QoQ | 382 0.0% YoY -5.9% QoQ | 352 -8.6% YoY -7.9% QoQ | 372 11.7% YoY 5.7% QoQ |
| 2023 | 428 5.4% YoY 15.1% QoQ | 419 9.7% YoY -2.1% QoQ | 394 11.9% YoY -6.0% QoQ | 418 12.4% YoY 6.1% QoQ |
| 2024 | 172 -59.8% YoY -58.9% QoQ | - | - | - |
The average 5 years interest of autoimmune diseases was 36.75 per week. The last year interest of autoimmune diseases compared to the last 5 years has changed by -13.77%. The interest for autoimmune diseases is seasonal. The last year interest is quite lower compared to 5 years ago. It has decreased by -33.23%.
There is not enough data for liver-directed gene therapy to provide analysis
There is not enough data for liver-directed gene therapy to provide correlation calculation
There is not enough data for liver-directed gene therapy to provide analysis
After 38 days of this quarter the interest is at 76.0. Based on that we can calculate that during remaining 53 days it will total up to 182.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 217 | 155 -28.6% QoQ | 233 50.3% QoQ | 60 -74.2% QoQ |
| 2020 | 213 -1.8% YoY 255.0% QoQ | 214 38.1% YoY 0.5% QoQ | 57 -75.5% YoY -73.4% QoQ | 131 118.3% YoY 129.8% QoQ |
| 2021 | 175 -17.8% YoY 33.6% QoQ | 184 -14.0% YoY 5.1% QoQ | 95 66.7% YoY -48.4% QoQ | 135 3.1% YoY 42.1% QoQ |
| 2022 | 113 -35.4% YoY -16.3% QoQ | 186 1.1% YoY 64.6% QoQ | 158 66.3% YoY -15.1% QoQ | 170 25.9% YoY 7.6% QoQ |
| 2023 | 151 33.6% YoY -11.2% QoQ | 256 37.6% YoY 69.5% QoQ | 196 24.1% YoY -23.4% QoQ | 154 -9.4% YoY -21.4% QoQ |
| 2024 | 76 -49.7% YoY -50.6% QoQ | - | - | - |
The average 5 years interest of ornithine transcarbamylase deficiency was 12.8 per week. The last year interest of ornithine transcarbamylase deficiency compared to the last 5 years has changed by 16.87%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -5.73%.
After 38 days of this quarter the interest is at 275.0. Based on that we can calculate that during remaining 53 days it will total up to 659.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 526 | 532 1.1% QoQ | 398 -25.2% QoQ | 535 34.4% QoQ |
| 2020 | 739 40.5% YoY 38.1% QoQ | 635 19.4% YoY -14.1% QoQ | 421 5.8% YoY -33.7% QoQ | 588 9.9% YoY 39.7% QoQ |
| 2021 | 664 -10.1% YoY 12.9% QoQ | 569 -10.4% YoY -14.3% QoQ | 455 8.1% YoY -20.0% QoQ | 567 -3.6% YoY 24.6% QoQ |
| 2022 | 819 23.3% YoY 44.4% QoQ | 827 45.3% YoY 1.0% QoQ | 482 5.9% YoY -41.7% QoQ | 805 42.0% YoY 67.0% QoQ |
| 2023 | 1028 25.5% YoY 27.7% QoQ | 753 -8.9% YoY -26.8% QoQ | 545 13.1% YoY -27.6% QoQ | 860 6.8% YoY 57.8% QoQ |
| 2024 | 275 -73.2% YoY -68.0% QoQ | - | - | - |
The average 5 years interest of hemophilia A was 50.09 per week. The last year interest of hemophilia A compared to the last 5 years has changed by 20.16%. The interest for hemophilia A is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 39.23%.
After 38 days of this quarter the interest is at 221.0. Based on that we can calculate that during remaining 53 days it will total up to 529.0. phenylketonuria expected interest is significantly lower compared to same quarter last year (-40.8%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 596 | 645 8.2% QoQ | 595 -7.8% QoQ | 684 15.0% QoQ |
| 2020 | 803 34.7% YoY 17.4% QoQ | 559 -13.3% YoY -30.4% QoQ | 498 -16.3% YoY -10.9% QoQ | 545 -20.3% YoY 9.4% QoQ |
| 2021 | 647 -19.4% YoY 18.7% QoQ | 543 -2.9% YoY -16.1% QoQ | 506 1.6% YoY -6.8% QoQ | 580 6.4% YoY 14.6% QoQ |
| 2022 | 746 15.3% YoY 28.6% QoQ | 745 37.2% YoY -0.1% QoQ | 592 17.0% YoY -20.5% QoQ | 687 18.4% YoY 16.0% QoQ |
| 2023 | 893 19.7% YoY 30.0% QoQ | 714 -4.2% YoY -20.0% QoQ | 578 -2.4% YoY -19.0% QoQ | 728 6.0% YoY 26.0% QoQ |
| 2024 | 221 -75.3% YoY -69.6% QoQ | - | - | - |
The average 5 years interest of phenylketonuria was 50.4 per week. The last year interest of phenylketonuria compared to the last 5 years has changed by 8.93%. The interest for phenylketonuria is seasonal. The last year interest is comparable to 5 years ago. It has changed only by 0.46%.
There is not enough data for Takeda Pharmaceuticals collaboration to provide analysis
There is not enough data for Takeda Pharmaceuticals collaboration to provide correlation calculation
There is not enough data for Takeda Pharmaceuticals collaboration to provide analysis